Skip to the beginning of the images gallery

ruboxistaurin , Protein kinase C beta inhibitor, CAS No.169939-94-0, Protein kinase C beta inhibitor

Moligand™

CAS#: 169939-94-0
Formula: C₂₈H₂₈N₄O₃
Molecular Weight: 468.5
PubChem CID: 153999

Item Number

R613331

Grouped product items
SKU	Size	Availability	Price	Qty
R613331-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,334.90
R613331-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,001.90

View related series

Pim-1 proto-oncogene，serine/threonine kinase Inhibitor Pim-2 proto-oncogene，serine/threonine kinase Inhibitor protein kinase C alpha Inhibitor protein kinase C beta Inhibitor protein kinase C delta Inhibitor protein kinase C gamma Inhibitor

Basic Description

Synonyms	Ruboxistaurin\|169939-94-0\|LY-333531\|Ruboxistaurin [INN]\|LY 333531\|LY333531\|721809WQCP\|K00587a\|(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione\|CHEMB
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	Protein kinase C beta inhibitor

Associated Targets

PIM1 Tchem Serine/threonine-protein kinase pim-1 1 Activities

Discover Target: PIM1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PIM2 Tchem Serine/threonine-protein kinase pim-2 1 Activities

Discover Target: PIM2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PIM3 Tchem Serine/threonine-protein kinase pim-3 2 Activities

Discover Target: PIM3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PRKCD Tclin Protein kinase C delta type 3 Activities

Discover Target: PRKCD

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PRKCB Tchem Protein kinase C beta type 8 Activities

Discover Target: PRKCB

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PRKCE Tchem Protein kinase C epsilon type 2 Activities

Discover Target: PRKCE

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PRKCG Tchem Protein kinase C gamma type 1 Activities

Discover Target: PRKCG

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PRKCA Tchem Protein kinase C alpha type 2 Activities

Discover Target: PRKCA

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PRKCQ Tchem Protein kinase C theta type 2 Activities

Discover Target: PRKCQ

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Names and Identifiers

IUPAC Name	(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione
INCHI	InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1
InChi Key	ZCBUQCWBWNUWSU-SFHVURJKSA-N
Canonical SMILES	CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O
Isomeric SMILES	CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O
Alternate CAS	169939-94-0
PubChem CID	153999
MeSH Entry Terms	13-((dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione;Arxxant;LY 333531;LY-333531;ruboxistaurin;ruboxistaurin mesilate hydrate
Molecular Weight	468.5

CAS Registry No.

Wikipedia

DiscoveRx TREEspot

PubChem CID

ChEMBL Ligand

RCSB PDB Ligand

DrugCentral Ligand

References

1. Budhiraja S, Singh J. (2008) Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.. Fundam Clin Pharmacol, 22 (3): (231-40). [PMID:18485142]
2. Wei L, Yin Z, Yuan Y, Hwang A, Lee A, Sun D, Li F, Di C, Zhang R, Cao F et al.. (2010) A PKC-beta inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats.. Microvasc Res, 80 (1): (158-65). [PMID:20079359]
3. Xu Y, Wang S, Feng L, Zhu Q, Xiang P, He B. (2010) Blockade of PKC-beta protects HUVEC from advanced glycation end products induced inflammation.. Int Immunopharmacol, 10 (12): (1552-9). [PMID:20875828]
4. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A et al.. (1996) (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.. J Med Chem, 39 (14): (2664-71). [PMID:8709095]
5. Tanaka M, Sagawa S, Hoshi J, Shimoma F, Matsuda I, Sakoda K, Sasase T, Shindo M, Inaba T. (2004) Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors.. Bioorg Med Chem Lett, 14 (20): (5171-4). [PMID:15380221]
6. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S. (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.. Proc Natl Acad Sci USA, 104 (51): (20523-8). [PMID:18077363]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.